Report from Hungary - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report from Hungary
Eastern Europe's pharmaceutical leader, Hungary, is working to maintain its number-one status while also pursuing new avenues, especially in biopharmaceuticals.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 16-18

Gedeon Richter, which is by far the largest Hungarian-owned pharmaceuticals company and the biggest domestically-owned drug manufacturer in Eastern Europe, has been setting the pace for the sector overall. The company has made acquisitions in Switzerland and Germany, with a focus on gynecology products and oral contraceptives.

Gideon Richter is also building a follow-on biologics plant in Debrecen in eastern Hungary with the aim of marketing biosimilars in Europe in two years. In late 2010, the company entered into a collaboration agreement with Mochida of Japan on the development and marketing of Richter's follow-on biologics in Japan.

Approximately 90% of Richter's €992 million ($1.4 billion) sales in 2010 came from abroad, mainly from Russia (22%), Poland, and Romania. The company's approach for remaining competitive in the long term is to maintain a portfolio of high-added value products.

"We are able to adopt this new strategy because we have the freedom of being an independent company without being owned by an international pharmaceutical company," says Zouzsa Beke, Richter's communications director. "We are also doing it without the backing of a strong government industrial policy like that in other EU countries. There are R&D incentives from the government but they are not significant, and capital allowances only apply to large investments."

Some of the Hungarian subsidiaries of international companies, such as Egis, which is majority-owned by Servier of France, are also planning to enter the follow-on biologics sector, although not necessarily as producers initially.

Hungary's National Economy Minister Gyorgy Matolcsy stated last month that the government wants the country to be one of the top 10 leading biotechnology centers in the European Union by 2020–2025.

However, small biopharmaceutical companies, which make up most of the fledgling biotech sector outside the multinational firms, complain about lack of funds from Hungarian financiers.

"The few venture capitalists are not interested in biotechnology because they don't understand it, and the banks are even more reluctant to invest in what they see as high risk innovations," explains Zsolt Lisziewicz, chief operating officer of Genetic Immunity, Budapest, a biopharmaceuticals start-up in nanomedicine immunotherapies. "We would like to build a plant in Hungary once we have a commercial product, but we may have to do a NASDAQ floatation to get the funds."

Hungary, which is outside the euro zone, is still gripped by a credit squeeze after having to be rescued by the International Monetary Fund (IMF) four years ago. With easier access to funds, its pharmaceuticals sector might be performing even better in the European markets.

Sean Milmo is a freelance writer based in Essex, UK.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here